Viewing research peptides. User acknowledges these products are not for human nor veterinary use. Review Legal Waiver →

CJC-1295 + Ipamorelin supplies a dual-action peptide matrix combining modified GRF 1-29 with the selective secretagogue Ipamorelin in a 1:1 stoichiometric ratio. In endocrine signaling models, this co-formulation allows dual-pathway study: amplifying GHRH receptor-mediated cyclic AMP production alongside ghrelin receptor-mediated intracellular calcium flux. Co-lyophilized to ensure lot-to-lot stoichiometric precision. Supplied strictly for laboratory research. Not for human or veterinary use.

Chemical & Analytical Specifications

Compound Identifier CJC-1295 + Ipamorelin Synergistic Blend
Sequence / Structure Mod GRF 1-29 (29-AA) & Ipamorelin (5-AA) Dual Matrix
Molecular Formula C152H252N44O42 + C38H49N9O5
Molecular Weight 3367.97 g/mol + 711.85 g/mol
CAS Number 863288-34-0 / 170851-70-4
Purity Specification ≥99.0% (HPLC & Mass Spectrometry)
Supplied Format Co-lyophilized vial
Research Classification Dual-receptor endocrine signaling matrix

Laboratory Handling & Solvent Protocols

To preserve structural integrity and peptide purity, lyophilized materials should be maintained at -20°C in an airtight container protected from ambient moisture and light. Reconstitution should be conducted under sterile conditions using bacteriostatic water (0.9% benzyl alcohol) or sterile laboratory saline. Allow the diluent to run gently down the interior vial wall; avoid vigorous shaking or vortexing to prevent shear-induced degradation. Reconstituted aliquots must be stored at 2°C to 8°C and evaluated within 28 to 30 days.

REGULATORY COMPLIANCE NOTICE All èvelan research products are strictly synthesized and supplied for laboratory research, analytical characterization, and scientific assay evaluation only. These materials are not intended, formulated, or approved for human, clinical, veterinary, or diagnostic application. Distribution is restricted to authorized personnel who affirm adherence to relevant institutional and laboratory safety protocols.

CJC-1295 + Ipamorelin Synergistic Blend

G$23,100.00

Research Pathways & Profile

CJC-1295 + Ipamorelin supplies a dual-action peptide matrix combining modified GRF 1-29 with the selective secretagogue Ipamorelin in a 1:1 stoichiometric ratio. In endocrine signaling models, this co-formulation allows dual-pathway study: amplifying GHRH receptor-mediated cyclic AMP production alongside ghrelin receptor-mediated intracellular calcium flux. Co-lyophilized to ensure lot-to-lot stoichiometric precision. Supplied strictly for laboratory research. Not for human or veterinary use.

Format & Concentration: 10mg Blend (5mg CJC + 5mg IPA)
≥99% HPLC Analytical Standard
Synthesized in Certified Facility
Direct Express Lab Fulfillment
Analytical Specifications & Sequence

Sequence: Mod GRF 1-29 (29-AA) & Ipamorelin (5-AA) Dual Matrix | Formula: C152H252N44O42 + C38H49N9O5 | Molecular Weight: 3367.97 g/mol + 711.85 g/mol | CAS Number: 863288-34-0 / 170851-70-4 | Purity: ≥99.0% (RP-HPLC, ESI-MS) | Sterile Lyophilized Formulation.

Handling, Solvent & Storage Guidelines

Laboratory Assay Standard. Storage: -20°C (lyophilized powder, protected from light) or 2°C to 8°C (short-term reconstituted solution). Reconstitution: Bacteriostatic water (0.9% benzyl alcohol) via sterile interior wall flow without vortexing. Strictly prohibited for human, veterinary, or clinical use.

1All peptide compounds cataloged are intended exclusively for laboratory research, biochemical assays, and analytical characterization. Strictly not for human, veterinary, diagnostic, or therapeutic administration.
2Analytical purity (≥99%) is validated via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). Compound integrity is dependent on adherence to cold-chain storage and inert handling protocols.
3The acquiring entity assumes sole responsibility for regulatory compliance, laboratory safety protocols, and safe handling in accordance with federal, state, and local standards. èvelan expressly disclaims liability for off-label or unapproved application.
View Full Legal & Research Disclaimer →